Takeda Sets Eyes to Globally Market AMAG’s Anemia Drug

doi:10.3833/pdr.v2010i4.1328

Pharma Deals Review, Vol 2010, No 4 (2010)

Takeda Sets Eyes to Globally Market AMAG’s Anemia Drug

PharmaDeals Analyst

Abstract

Osaka based pharma giant Takeda Pharmaceuticals and AMAG Pharmaceutical announce an exclusive licensing deal, potentially worth USD 280 M, to market Feraheme® (ferumoxytol) globally, a therapeutic iron compound to treat iron deficiency anemia (IDA).

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.